Endonovo Therapeutics (ENDV) EBT (2016 - 2023)
Endonovo Therapeutics has reported EBT over the past 12 years, most recently at -$766170.0 for Q3 2023.
- Quarterly results put EBT at -$766170.0 for Q3 2023, down 26.98% from a year ago — trailing twelve months through Sep 2023 was -$4.4 million (down 39.98% YoY), and the annual figure for FY2022 was -$18.5 million, down 495.02%.
- EBT for Q3 2023 was -$766170.0 at Endonovo Therapeutics, down from $2.1 million in the prior quarter.
- Over the last five years, EBT for ENDV hit a ceiling of $7.2 million in Q1 2023 and a floor of -$12.9 million in Q4 2022.
- Median EBT over the past 5 years was -$1.5 million (2021), compared with a mean of -$1.6 million.
- Biggest five-year swings in EBT: tumbled 639.66% in 2022 and later surged 399.62% in 2023.
- Endonovo Therapeutics' EBT stood at -$5.7 million in 2019, then surged by 64.16% to -$2.0 million in 2020, then surged by 218.03% to $2.4 million in 2021, then tumbled by 639.66% to -$12.9 million in 2022, then soared by 94.08% to -$766170.0 in 2023.
- The last three reported values for EBT were -$766170.0 (Q3 2023), $2.1 million (Q2 2023), and $7.2 million (Q1 2023) per Business Quant data.